Related Experiment Video
Updated: May 10, 2026
05:02
Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells
Published on: February 4, 2021
Bone metastasis from breast cancer involves elevated IL-11 expression and the gp130/STAT3 pathway
Li Ren1, Xia Wang, Zuoliang Dong
1Department of Laboratory, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, People's Republic of China. roland-li@163.com
Medical Oncology (Northwood, London, England)
|July 2, 2013
Summary
Interleukin-11 (IL-11) is significantly elevated in breast cancer patients with bone metastasis (MBC-B) compared to those with primary breast cancer (PBC). Higher IL-11 levels correlate with increased bone metastasis, suggesting its potential as a predictive biomarker.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Breast cancer is a leading cause of cancer-related mortality worldwide.
- Bone metastasis is a common and serious complication of breast cancer, significantly impacting patient prognosis and quality of life.
- The molecular mechanisms underlying breast cancer bone metastasis are not fully understood, necessitating further research into key signaling pathways and biomarkers.
Purpose of the Study:
- To investigate the association between Interleukin-11 (IL-11) and bone metastasis in breast cancer patients.
- To explore the potential molecular mechanisms involving IL-11 in the development of breast cancer bone metastasis.
- To evaluate IL-11 as a potential biomarker for predicting bone metastasis in breast cancer.
Main Methods:
- Serum samples from 180 breast cancer patients and 20 healthy controls were analyzed for IL-11, CTGF, TGF-β, and Tracp5b levels using ELISA.
- IL-11 mRNA expression in tumor tissues was assessed by RT-PCR.
- Immunohistochemistry was used to detect IL-11 and CTGF protein expression.
- Western blot analysis identified the expression of p-38, p-C-JUN, p-STAT3, and p-gp130.
- Electrophoretic mobility shift assay (EMSA) determined AP-1 DNA-binding activity.
Main Results:
- Serum IL-11 levels and mRNA expression were significantly higher in patients with breast cancer metastatic to bone (MBC-B) compared to those with primary breast cancer (PBC).
- Immunohistochemical analysis revealed a higher percentage of IL-11 positive cells in MBC-B tissues (57.5%) versus PBC tissues (14.29%).
- Elevated expression of p-38, p-C-JUN, p-STAT3, and p-gp130, along with increased AP-1 DNA-binding activity, was observed in the MBC-B group.
Conclusions:
- Interleukin-11 (IL-11) is significantly associated with the presence and progression of bone metastasis in breast cancer patients.
- The findings suggest that IL-11 may play a crucial role in the molecular pathways driving breast cancer bone metastasis.
- IL-11 demonstrates potential as a valuable biomarker for the early prediction of bone metastasis in breast cancer.
Related Concept Videos
02:30Metastasis
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...